Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | MME | P08473 | 3/20 | 0.58 |
| ▸ | ATM | Q13315 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24155192 | 0.92 | REN (0.59) | MMECTSSCTSKCTSLCTSB | |
| SCHEMBL24155357 | 0.92 | REN (0.59) | MMECTSSCTSKCTSLCTSB | |
| SCHEMBL24155272 | 0.91 | KLK5 (0.59) | ACEATMCTSSCTSKCTSL | |
| SCHEMBL24155191 | 0.91 | CTSS (0.52) | ACEMMEATMKMT2AMEN1 | |
| SCHEMBL29602242 | 0.90 | KMT2A (0.67) | ACEATMKMT2AMEN1CTSS | |
| SCHEMBL8130179 | 0.90 | KMT2A (0.67) | ACEATMKMT2AMEN1CTSS | |
| SCHEMBL29484184 | 0.88 | KMT2A (0.66) | ACEATMKMT2AMEN1CTSS | |
| SCHEMBL8961019 | 0.86 | ACE (0.60) | ACEMMEATMKMT2AMEN1 | |
| SCHEMBL8961015 | 0.86 | ACE (0.60) | ACEMMEATMKMT2AMEN1 | |
| SCHEMBL24155190 | 0.86 | REN (0.58) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021262173-A1 | PEPTIDES FOR TREATMENT OF MEDICAL DISORDERS | Humanwell Pharmaceutical US (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210403505-A1 | PEPTIDES FOR TREATMENT OF MEDICAL DISORDERS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403505-A1 | PEPTIDES FOR TREATMENT OF MEDICAL DISORDERS | OPRK1, OPRL1, OPRM1 | ACE 1565/4885MME 261/4885ATM 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.